Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).

  • FEAnalytics.com
  • FEInvest.net
  • FETransmission.com
  • Investegate.co.uk
  • Trustnet.hk
  • Trustnetoffshore.com
  • Trustnetmiddleeast.com

For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.

WHAT INFORMATION DO WE COLLECT ABOUT YOU?

We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.

COOKIES

In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.

HOW WE USE INFORMATION

We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.

ACCESS TO YOUR INFORMATION AND CORRECTION

We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.

WHERE WE STORE YOUR PERSONAL DATA

The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.

CHANGES TO OUR PRIVACY POLICY

Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.

OTHER WEBSITES

Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.

CONTACT

If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

WideCells Group PLC (WDC)

  Print      Mail a friend

Wednesday 11 October, 2017

WideCells Group PLC

Partner Secured to Expand into MENA & Asia-Pacific

RNS Number : 2510T
WideCells Group PLC
11 October 2017
 

11 October 2017

WideCells Group PLC ('WideCells Group' or 'the Group')

 

Strategic Partner Secured to Expand into

The Middle East, North Africa and Asia-Pacific Territories

 

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground-breaking insurance for stem cell treatment, is pleased to announce that it has signed an exclusive Heads of Terms agreement with multi-sector advisory business White Apex General Trading ('White Apex'), to sell and promote the Group's stem cell services in the Middle East and North Africa ('MENA') and Asia-Pacific (excluding China) territories (the 'Territories'). 

 

Overview

·     Expansion into the Territories through exclusive strategic partnership with White Apex

·     Initial three-year binding agreement expected to be secured by 31 October 2017

·     Payment of £255,000 will follow completion of the formal agreement with recurring revenues to be generated thereafter

·     White Apex has option to require WideCells to develop Wideacademy in MENA, upon payment of additional £250,000, prior to 31 December 2017

·     Deal highlights global roll-out potential through securing worldwide commercial partners

·     Services to be promoted and sold across all three WideCells Group divisions 

·     New office to be established in Dubai headed by Dr Ahmed Alawi, a preeminent doctor in the stem cell sector

 

WideCells Group CEO, João Andrade, said, "This agreement is an historic achievement.  Not only is this the strongest strategic deal we have secured to date, but it marks our move into a significant new region: MENA and Asia-Pacific.  Crucially, revenues are expected to commence by the end of this year, with £255,000 to be paid following signing of the binding agreement, which is anticipated by 31 October 2017, and further revenues expected to follow in the near term with at least £250,000 targeted before the end of the year and similar numbers targeted year on year thereafter.  These figures will gain even more traction as we continue our expansion strategy and increase our global profile.  This agreement highlights how rapidly we can grow and we are committed to securing similar commercial partnerships as we transform the value fundamentals of our company."

 

Dr Ahmed Alawi said, "We are proud of our partnership with Widecells Group as we focus on creating a new paradigm and future medicine for our people.  Our aim is to improve lives and create hope; we believe this partnership will enable us to achieve these goals."

 

Further Information

WideCells Group anticipates that a formal binding three-year agreement will be secured with White Apex by 31 October 2017, at which point revenue generation for the Group will begin; £255,000 will be paid following signing of the agreement, and recurring revenues are expected to commence thereafter.  White Apex is a multi-sector advisory business with offices in the UAE, Oman, Bahrain and Kuwait.  The company supports clients across four primary divisions - Corporate Advisory, Investment, Energy and Healthcare - and is experienced in the marketing and sale of commercial products.

 

WideCells Group will be able to leverage White Apex's established infrastructure and intends to establish a regional office in Dubai, which will be run by a team from White Apex.  This team will be led by Dr. Ahmed Alawi, who will become WideCells Group Managing Director of MENA and Asia-Pacific.  Dr. Alawi is an experienced stem cell scientist who previously led a team at Genzyme, which was the world's third-largest biotechnology company in 2010, prior to its acquisition by Sanofi in 2011.  He also founded The Middle East Thrombosis Institute (www.tri-london.ac.uk).  Alongside his medical achievements, Dr. Alawi has considerable cross functional experience in international Fortune 500 & FTSE companies, having previously held roles at Philips Electronics and Shell International.  He also has notable regional connections, having previously worked within the Omani Government and most recently co-founded RAY International UAE in 2015, which is part of the leading RAY International Group (http://rayinternational.ae).

 

Other team members include Ahmad Jemain, who will become WideCells Group Chief Operating Officer of MENA and Asia-Pacific.  Mr Jemain has considerable experience in corporate and enterprise in the South East Asian region, particularly within the insurance industry.  Zakaria Aziz will also join the team as WideCells Group Business Development/ Marketing in South East Asia.  Mr Aziz is a successful entrepreneur who co-founded RAY Oman Group, which is part of the leading RAY International Group.  He has over 28 years of business experience in the oil and gas sectors in both South-East Asia and the Middle East. 

 

Under the terms of the initial three-year agreement, White Apex will sell and promote the following WideCells Group services:

 

·     WideCells, stem cell collection and dispatch - covers the processing, quality control, analysis (infectious disease screening) and long-term storage (up to 25 years) of cord blood and/or cord tissue

An initial start-up fee of £15,000 payable to WideCells Group on completion of formal binding agreement followed by on-going monthly support fees

Additional ongoing revenue from cord blood and tissue storage - White Apex to procure clients in the UAE and send samples to WideCells Group's Institute of Stem Cell Technology laboratory in Manchester

 

·     INDUS, a novel synthetic bone graft which promotes new bone formation.  Two products will be available for purchase - INDUS TCP and INDUS BCP

White Apex will be appointed as Distributor and authorised to sell INDUS directly to customers (such as clinics or dentists) or to appoint sub-dealers within the Territories

Minimum sales targets will be agreed and established in the first 90 days when entering each country within the Territories

 

·     CellPlan, the world's first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process

White Apex to facilitate introductions between CellPlan and insurance companies in the Territories with a view to securing commercial sales agreements

Potential for White Apex to introduce CellPlan to stem cell storage facilities and provide ongoing support

CellPlan will pay White Apex introductory commission fees

 

·     Wideacademy, providing stem cell education and training services via a custom-built Statistical Analysis System ('SaaS') platform

 

Paid for subscriptions for doctors and medical professionals to access premium content and digital tools - charged at £120 per year per subscriber/ doctor

§ White Apex to initially sponsor subscriptions for 2,000 doctors per year for two countries in the agreed Territories a period of three years - generating revenues of £240,000 by signing of the formal agreement - White Apex is expected to generate further sponsorship in its designated territories

§ Payment for the first 2,000 doctors is due to Wideacademy on conclusion of the formal binding agreement

§ Thereafter, revenues generated from all future subscriptions secured in the Territories will be shared between Wideacademy and White Apex

 

Wideacademy platform localised to the MENA region

§ White Apex has the right to pay £250,000 before 31 December 2017 for Wideacademy to localise its bespoke SaaS platform for use in the MENA region

 

Accreditation 

§ Wideacademy will offer courseware modules to Medical and Enterprise professionals to enhance their CPD (continuous professional development) - it is anticipated that these modules will be free-to-access, but the optional micro credential accreditation which comes from completion will be charged at c. £200 per module

§ Wideacademy will share with White Apex 30% of revenues derived from accreditation of online courses from users in the Territories

 

Licensing of the Wideacademy white-labelled platform

§ Opportunity for the Wideacademy platform to be used to drive Education, Thought Leadership and Knowledge Management in other areas of medicine outside of stem cells, e.g. Dementia, Cancer and other major health challenges

§ White-labelled platforms for areas outside stem cells to be available at a licence fee of approximately £500,000 in the first year and £250,000 in the following years (per annum)

§ Wideacademy will share revenues derived from such licensing deals introduced by White Apex with the company within the designated Territories

 

**ENDS**

 

For further information, please visit the Company's website www.widecellsgroup.com, follow us on Twitter @WideCells_Group or contact:

 

WideCells Group

CEO - João Andrade

Tel:  +351 919 033 171

Smaller Company Capital Ltd

Broker - Jeremy Woodgate & Rupert Williams

Tel: +44 (0) 20 3651 2912

Shard Capital Partners LLP

Broker - Damon Heath & Erik Woolgar

Tel: +44 (0) 20 7186 9950

St Brides Partners Ltd

PR - Charlotte Page & Olivia Vita

Tel: +44 (0) 20 7236 1177

 

Notes to Editors

 

WideCells Group PLC

WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments accessible and affordable.  In June 2017, the Group was ranked as the 21st most disruptive company globally by DISRUPT 100, an annual index celebrating the businesses with the most potential to influence, change or create new global markets.

 

The Group has three divisions:

·    CellPlan: the world's first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process

·    WideCells: The Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Centre to focus on stem cell research and regenerative medicine. WideCells also has international cryogenics divisions specialising in stem cell storage.

·    Wideacademy: developing an education and training division to promote awareness of the benefits of stem cell storage across the global general practice community.

 

The Group has built an experienced senior management team that has been integral to the development of its growth and business to date.

 

Stem Cell Fast Facts:

·    Cord blood (which is taken from the umbilical cord) provides the most effective source of stem cells for families due to it being simple, safe and painless to collect relative to other sources of stem cells such as bone marrow - WideCells will focus on promoting the collection and storage of this.

·    Since 2005, there has been a 300% increase in the number of illnesses that can be treated using stem cells

·    82 illnesses can currently be treated using stem cell procedures

·    Despite initial storage often costing no more than a few £thousand, actual treatment can cost in the £hundreds of thousands

 

 

White Apex General Trading

White Apex is a boutique advisory business covering wide spectrum of services.  Rooted in engineering projects, over the years, the company has become a multi-sector, global advisory business focused on building highly valued relationships with individuals, corporates, institutions and Governments. Today, the company supports clients across four divisions:

 

·     Corporate Advisory

·     Investment

·     Energy

·     Healthcare

 

White Apex is a privately owned, dynamic company combining the diverse, complementary talents of a multi skilled team with global experience. The company prides itself on its integrity, agility and client-led, partnering approach. It invests time in developing a deep understanding of their clients' needs - partnering with them to provide solutions that enable their business, protect their assets and grow their capital. Whether their priority is empowering their business, increasing their presence, White Apex have the sector understanding and proactive risk management expertise to help them make the right decision at the right time and with the right people. They believe that by combining these qualities and experience they offer a distinct and compelling offering that sets the company apart from other firms. More importantly, these attributes help their clients solve the most exacting challenges and seize opportunities.

 

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR).


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGREAPEEFFAXFFF

a d v e r t i s e m e n t